The vision of the Munich Biotech Cluster is to establish it as an international excellence and model region for personalised and target-oriented medicine.
The faster way to more effective and safer medicine
The field of personalised medicine is a major future market. Diagnosis and therapy concepts are developed here which are tailored to the patient's individual predispositions and symptoms. A key issue is meeting the challenges of today's drug development such as improving safety and efficacy, reducing development periods and cutting costs.
Solving precisely these issues is the focus of the Munich Biotech Cluster, which takes the entire value-added chain into consideration with its strategic concept "m4 - a new dimension in drug development" and aims to ensure its sustainable improvement at the location. The site will be further strengthened by new, cross-institutional infrastructures such as IT data management, central services for clinical studies and the Munich Biobank Alliance.
Over 100 partners from the midmarket biotech industry, large corporations, scientific institutions and clinics in and around Munich work together in the cluster on over 40 projects in the areas oncology and cardiovascular and autoimmune diseases.
Today, Munich is already one of the leading pharmaceutical and biotechnology locations in Europe. The vision of the Leading-Edge Cluster is to establish it as an international excellence and model region for personalised and target-oriented medicine.
Deutsche Version dieser Seite